|
Originally published In Press as doi:10.1074/jbc.M800184200 on March 10, 2008
J. Biol. Chem., Vol. 283, Issue 19, 13100-13107, May 9, 2008
Culturing of Human Mesenchymal Stem Cells as Three-dimensional Aggregates Induces Functional Expression of CXCR4 That Regulates Adhesion to Endothelial Cells*
Irina A. Potapova,
Peter R. Brink,
Ira S. Cohen, and
Sergey V. Doronin1
From the
Department of Physiology and Biophysics, Institute of Molecular Cardiology, Stony Brook University, Stony Brook, New York 11794
Culture-expanded human mesenchymal stem cells (hMSCs) are increasingly used in a variety of preclinical and clinical studies. However, these cells have a low rate of engraftment to bone marrow or damaged tissues. Several laboratories have shown that during isolation and subculturing mesenchymal stem cells quickly lose the expression of CXCR4, the key receptor responsible for lymphocytes and hematopoietic stem cell homing. Here we show that culturing of hMSCs as three-dimensional aggregates (hMSC spheroids) restores CXCR4 functional expression. Expression of CXCR4 inversely correlates with the secretion of SDF-1 by hMSCs. Cells from hMSC spheroids up-regulate expression of CD49b, the 2 integrin subunit, and suppress the expression of CD49d, the 4 integrin subunit. Transfer of cells from the spheroids back to a monolayer suppresses the expression of CXCR4 and CD49b and restores the expression of CD49d. Treatment of cells from the spheroids with SDF-1 leads to CXCR4 internalization and activation of ERK-1,2. Adhesion of hMSCs to human umbilical vein endothelial cells (HUVECs) was investigated. SDF-1, AMD-3100, or exposure of HUVECs to hypoxia did not affect adhesion of hMSCs from a monolayer to HUVECs. Adhesion of cells from hMSC spheroids to HUVECs was stimulated by SDF-1, AMD-3100, or by exposure of HUVECs to hypoxia. Stimulatory effects of hypoxia and addition of SDF-1 or AMD-3100 were not additive. Overall, our data indicate that the expression of CXCR4 by hMSCs regulates hMSC adhesion to endothelial cells.
Received for publication, January 9, 2008
, and in revised form, March 10, 2008.
* This work was supported, in whole or in part, by National Institutes of Health Grants HL67101 and HL28958. This work was also supported by an American Heart Association Scientist Development grant (to S. V. D.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. S1–S4.
1 To whom correspondence should be addressed: Dept. of Physiology and Biophysics, BST-6, Rm. 124, Stony Brook University, Stony Brook, NY 11794. Tel.: 631-444-7373; Fax: 631-444-3432; E-mail: sdoronin{at}notes.cc.sunysb.edu.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
P. A. Walker, S. K. Shah, M. T. Harting, and C. S. Cox Jr
Progenitor cell therapies for traumatic brain injury: barriers and opportunities in translation
Dis. Model. Mech.,
January 1, 2009;
2(1-2):
23 - 38.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2008 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|